Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stimuvax plus hormonal therapy versus placebo plus hormonal therapy in first-line advanced hormone receptor-positive breast cancer
NL-OMON33179Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Stimuvax + hormonal therapy with Placebo + hormonal therapy (2 arms). Primary endpoint: Progression-free survival. Started Jul 2010; status: active, not recruiting.
02
Drugs
tecemotide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON33179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33179.